Latest News

Date Title Topic
19 Dec 2013 Systems medicine paves the way for improved treatment for AML patients Personalised medicine - Translational research - Haematologic malignancies
18 Dec 2013 Misunderstanding of Palliative Care Palliative and supportive care
17 Dec 2013 ESMO Signalling Pathways Symposium 2014: targeting the PI3K/AKT/mTOR pathway
17 Dec 2013 A Study of Anastrozole in Breast Cancer Chemoprevention Breast cancer - Cancer prevention
16 Dec 2013 Obinutuzumab/Chlorambucil in the First-Line Treatment of Older CLL Patients Cancer in Special Situations - Haematologic malignancies - Anticancer agents & Biologic therapy
13 Dec 2013 ESMO Press Release: Defending Medical Oncology to Assure Quality Care for Cancer Patients
12 Dec 2013 Phase III Study of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukaemia Haematologic malignancies - Anticancer agents & Biologic therapy
11 Dec 2013 CALR Mutations in Myeloproliferative Neoplasms Translational research - Haematologic malignancies
Pre-IMPAKT 2014 Training Course
09 Dec 2013 Learning From the FDA Breakthrough Therapies Pathway Bioethics, legal and economic issues - Anticancer agents & Biologic therapy
Alan Howard, ESMO’s Chief Executive Officer since 2009, has announced he is stepping down, to become effective as of January 2014.
05 Dec 2013 APO-SYS: How Modulation of Apoptosis Can be Used in the Treatment of Cancer and AIDS Translational research
ESMO German National Representative Elections
04 Dec 2013 Onartuzumab in Combination with Erlotinib in Patients with Advanced NSCLC Lung and other thoracic tumours - Anticancer agents & Biologic therapy